.png)
.png)
BIA Webinar - How to communicate your R&D to investors and the public
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. Our best practice guide, developed in collaboration with Consilium Strategic Communications, Instinctif Partners and Simmons & Simmons, was published in January to help members maintain understanding and trust through their communications.
In this webinar we will present the four principles of the guide and discuss how they can be implemented in practice. There will also be the opportunity to pose your own questions to the panel.
Chair
Sue Charles
A biotechnology entrepreneur and communications professional, Sue has over three decades of experience in the life sciences industry. Passionate about helping to translate bioscience innovations into commercial and investor success, Sue’s global experience covers advising early stage private to large multinational companies, supporting clients as they grow, including through successful financings both privately and on public markets. She has experience across breath of technology and therapeutic areas, including AMR. Through her consultancy business, Charles Consultants (Life Sciences), she advises senior executives and boards of life sciences companies, venture firms and science-led organisations providing strategic communications counsel. She also serves on the Board of private genomics tools company, RevoluGen, where she is also part-time head of corporate communications, and is a senior strategic advisor for Consilium Strategic Communications and Scius Communications. She is a founding member of the WHO Taskforce of AMR Survivors and serves on the Strategic Advisory Council of PACE. Widely recognised for pioneering the life sciences communications sector in the UK, Sue has founded, grown and led notable business communications consultancies including De Facto, Northbank, College Hill Life Sciences and Instnctif Partners (Healthcare & Life Sciences), building and leading teams in the UK, Germany, Australia and the USA. Previous part-time executive roles have included as Industry Engagement Manager at the ithree institute at the University of Technology Sydney and as CEO of a biotech spin-out from UCL. She has served on the Board of the UK BioIndustry Association (2018-2020) and as charity board trustee for the Jane Goodall Institute (UK) (2009 – 2011). Sue has a first-class degree and MA in Biochemistry from Oxford University, PhD-level research experience in molecular biology from Leicester University and an MBA from Cranfield Business School.
Speakers
Theodora Bloom
Theodora Bloom is executive editor of The BMJ, where her responsibilities include operations in print and online, as well as budgetary, ethical and policy matters. She has worked in biomedical publishing since 1992, initially as an editor on the biology team at Nature, and then on the founding team of Current Biology. After a number of years helping to develop Current Biology and its siblings Structure and Chemistry & Biology, Theo joined the beginnings of the open access movement. As the founding editor of Genome Biology she was closely involved in the birth of the commercial open access publisher BioMed Central, where she remained for several years, ultimately as Editorial Director for Biology. After a spell as a freelance publishing consultant working with a variety of clients, including a medical communications agency, she joined the non-profit open access publisher Public Library of Science (PLOS) in 2008, first as chief editor of PLOS Biology and later as Biology Editorial Director with additional responsibility for PLOS Computational Biology and PLOS Genetics. She also took the lead for PLOS on issues around data access and availability. She chairs the scientific advisory board for EMBL-EBI Literature Services (http://www.ebi.ac.uk/services/literature). Until recently she served on the boards of NAM Publications (www.aidsmap.com) and the Dryad digital repository (www.datadryad.org), and on the Genome Canada Data Sharing Policies Advisory Committee.
Brough Ranson
Brough joined N+1 Singer in October 2013 from the Healthcare team at Nomura Code. Previously, Brough has worked as a specialist salesman at Nomura, Merrill Lynch and ING. In over 20 years in the Healthcare sector Brough has been involved in IPOs and fundraisings across Europe for a wide variety of companies from Roche and Alcon to Eco Animal Health, Summit Therapeutics, Realm Therapeutics, Verona and Skyepharma. Brough has a degree in Politics and a Masters in Business Administration from Exeter University.
Chris Sampson
Chris has over fifteen years of experience in corporate, financial, product and internal communications at national, regional, and group levels. He currently serves as the Director of Corporate Communications for BTG plc, a global healthcare company focused on interventional medicine. Chris is responsible for developing and implementing the company’s corporate communications strategy. He leads proactive public relations and internal communication programmes that promote an understanding of BTG’s business, strategy, and values. Chris previously held a series of roles with the global biopharmaceutical company AstraZeneca, including as a member of the global media relations team and as Director of Communications for the company’s fast-growing Respiratory, Inflammation and AutoImmune portfolio. He holds a BA in communications with a minor in government from Suffolk University in Boston, Massachusetts.
Elizabeth Klein
Prior to founding her own consultancy, Elizabeth was an award-winning and highly-rated senior research analyst focused on the Life Sciences and IP Commercialisation sectors. Over 15 years at N+1 Singer, Teathers, Bridgewell, R.W. Baird and Dresdner Kleinwort Benson she developed an extensive network of client relationships and worked closely with a number of businesses in these sectors. She was the Starmine Healthcare Stockpicker of the Year in both 2006 and 2013, and was highly rated in the Extel survey over much of her career in investment banking. In 2015, Elizabeth founded Klein-Edmonds Associates, advising organisations in the biotechnology sector on their engagement and interaction with investors. She has consulted with Bioscience Managers since June 2017. Other clients: The BioIndustry Association, Radnor Capital, and Biotech & Money, and small businesses (Angel to pre-IPO) on corporate and investment strategy. Elizabeth is also a Trustee at the Royal National Orthopaedic Hospital (at Stanmore) Charity. Elizabeth has a 1st Class BSc in Applied Biology with Genetics from the University of Liverpool, an MBA from Imperial College Business School and an MA (Merit) in Medicine, Science & Society (History of Medicine) from Birkbeck, University of London.
In partnership with
BIA Annual Supporters
